BACTI B logo

Bactiguard Holding AB (publ) Stock Price

OM:BACTI B Community·SEK 606.3m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

BACTI B Share Price Performance

SEK 17.30
-17.60 (-50.43%)
SEK 42.00
Fair Value
SEK 17.30
-17.60 (-50.43%)
58.8% undervalued intrinsic discount
SEK 42.00
Fair Value
Price SEK 17.30
AnalystHighTarget SEK 42.00
AnalystLowTarget SEK 22.50
AnalystConsensusTarget SEK 38.75

BACTI B Community Narratives

AnalystHighTarget·
Fair Value SEK 42 58.8% undervalued intrinsic discount

Licensing Partnerships And Infection Prevention Tailwinds Will Transform This Medtech Coating Platform

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystLowTarget·
Fair Value SEK 22.5 23.1% undervalued intrinsic discount

Long Commercialization Cycles And Partner Dependence Will Eventually Support Infection Prevention Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value SEK 38.75 55.4% undervalued intrinsic discount

Infection Prevention Demand Will Drive Licensing Revenue And Margin Expansion Over The Coming Years

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
SEK 22.5
23.1% undervalued intrinsic discount
Revenue
10.28% p.a.
Profit Margin
10.65%
Future PE
30.41x
Price in 2029
SEK 27.01
SEK 42
58.8% undervalued intrinsic discount
Revenue
10.31% p.a.
Profit Margin
10.34%
Future PE
58.47x
Price in 2029
SEK 50.44
SEK 38.75
55.4% undervalued intrinsic discount
Revenue
12.23% p.a.
Profit Margin
15.38%
Future PE
34.42x
Price in 2028
SEK 46.51

Trending Discussion

Updated Narratives

BACTI B logo

Long Commercialization Cycles And Partner Dependence Will Eventually Support Infection Prevention Potential

Fair Value: SEK 22.5 23.1% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BACTI B logo

Licensing Partnerships And Infection Prevention Tailwinds Will Transform This Medtech Coating Platform

Fair Value: SEK 42 58.8% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BACTI B logo

Infection Prevention Demand Will Drive Licensing Revenue And Margin Expansion Over The Coming Years

Fair Value: SEK 38.75 55.4% undervalued intrinsic discount
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with reasonable growth potential.

2 Risks
3 Rewards

Bactiguard Holding AB (publ) Key Details

SEK 217.8m

Revenue

SEK 29.7m

Cost of Revenue

SEK 188.1m

Gross Profit

SEK 209.4m

Other Expenses

-SEK 21.3m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 05, 2026
-0.61
86.36%
-9.77%
39.9%
View Full Analysis

About BACTI B

Founded
2005
Employees
157
CEO
Christine Lind
WebsiteView website
www.bactiguard.com

Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas. It also operates through license partnerships with global MedTech companies that apply the technology to medical devices and sell them under own brand and co-branded. The company also has a portfolio of wound management products, such as Hydrocyn Aqua, an antimicrobial solution and gel for improved wound healing; and surgical sutures comprising non-absorbable, natural absorbable, synthetic absorable, and specialty sutures. It operates in the United States, Sweden, Malaysia, India, Bangladesh, Indonesia, the Kingdom of Saudi Arabia, and internationally. The company has licensed partnership with Becton, Dickinson & Company for urinary catheter bardex IC and lubrisil IC; Well Lead Medical for catheters and tubes; and Zimmer Biomet for orthopedic trauma implants. The company was founded in 2005 and is headquartered in Stockholm, Sweden.